Power3 Medical Products Inc announces that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro® protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept®, Exelon®, and Namenda®.

These results relate to the genetically distinct groups of Alzheimer’s disease patients, ie, those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

Power3 has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals. Power3 also plans to demonstrate the clinical application and benefits of its NuroPro diagnostic tests to healthcare providers located throughout the world. Power3 believes that this will assist the company greatly in an effort to generate sales of its NuroPro diagnostic tests. Power3 is currently working on a joint distribution effort with a number of potential business partners, such as the companies mentioned above, for the sale of its NuroPro diagnostic tests and the development of new drugs.

“This new and amazing discovery will help clarify some of the clinical observations and overcome difficulties that we have had as physicians, not only by helping us choose more appropriate treatment and better predict response, but also by helping us find more permanent treatments for the dementias,” said Dr Bosquez.

Ira L. Goldknopf, PhD, president and chief scientific officer of Power3, stated, “This innovation will provide physicians with an invaluable perspective to use in the treatment of their patients and will have profound implications for the diagnosis and treatment of Alzheimer’s disease, and for other diseases as well.”

Source: Power3 Medical Products